BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Encoded Therapeutics\, Inc. readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of studies Encoded Therapeutics\, Inc.'s dru
 gs run\, from ClinicalTrials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT05419492-9007@assetmemo.bio
DTSTAMP:20261121T010136Z
DTSTART;VALUE=DATE:20280630
DTEND;VALUE=DATE:20280701
SUMMARY:ETX101: Phase 1/2 readout est. (NCT05419492)
DESCRIPTION:ETX101\, phase 1/2\, Epilepsy.\nStudy: A Clinical Study to Eval
 uate the Safety and Efficacy of ETX101 in Infants and Children With SCN1A-
 Positive Dravet Syndrome\nEstimated primary completion: June 2028. This is
  a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can
  move.\nDrug page: https://assetmemo.bio/drug/etx101#upcoming-events\nRegi
 stry record: https://clinicaltrials.gov/study/NCT05419492
URL:https://assetmemo.bio/drug/etx101#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06112275-9007@assetmemo.bio
DTSTAMP:20261121T010136Z
DTSTART;VALUE=DATE:20300930
DTEND;VALUE=DATE:20301001
SUMMARY:ETX101: Phase 1/2 readout est. (NCT06112275)
DESCRIPTION:ETX101\, phase 1/2\, Epilepsy.\nStudy: A Clinical Study to Eval
 uate the Safety and Efficacy of ETX101\, an AAV9-Delivered Gene Therapy in
  Children With SCN1A-positive Dravet Syndrome (Australia Only)\nEstimated 
 primary completion: September 2030. This is a ClinicalTrials.gov estimate\
 , not a confirmed readout date\, and it can move.\nDrug page: https://asse
 tmemo.bio/drug/etx101#upcoming-events\nRegistry record: https://clinicaltr
 ials.gov/study/NCT06112275
URL:https://assetmemo.bio/drug/etx101#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06283212-9007@assetmemo.bio
DTSTAMP:20261121T010136Z
DTSTART;VALUE=DATE:20301031
DTEND;VALUE=DATE:20301101
SUMMARY:ETX101: Phase 1/2 readout est. (NCT06283212)
DESCRIPTION:ETX101\, phase 1/2\, Epilepsy.\nStudy: A Clinical Study to Eval
 uate the Safety and Efficacy of ETX101\, an AAV9-Delivered Gene Therapy in
  Children With SCN1A-positive Dravet Syndrome\nEstimated primary completio
 n: October 2030. This is a ClinicalTrials.gov estimate\, not a confirmed r
 eadout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/etx1
 01#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0
 6283212
URL:https://assetmemo.bio/drug/etx101#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
